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background:  In pts at extreme risk (ER) for surgery, CoreValve transcatheter aortic valve replacement (TAVR) is superior to optimal 
medical therapy. Pts with end stage renal disease (ESRD) on renal replacement therapy have generally been excluded from clinical trials 
and early outcomes after TAVR in these pts has not been reported.
methods:  Pts with ESRD who were deemed ER for surgery who had NYHA class II or greater symptoms were enrolled in the CoreValve 
US Expanded Use Study. Severe aortic stenosis was defined as an aortic valve area ≤ 0.8 cm2 or aortic valve index ≤ 0.5 cm2/m2 and 
either a mean aortic gradient > 40 mm Hg or a peak velocity > 4.0 M/sec. Early outcomes were assessed by 30 day all cause mortality or 
major stroke, and compared to pts enrolled in the US Pivotal ER Study.
results:  87 ESRD pts with attempted implant were enrolled in the Expanded Use Study. Compared to the 639 attempted implant pts in 
the US Pivotal Study without ESRD, pts with ESRD were younger (75.4 ± 8.8 vs. 83.2 ± 8.4 years; P < 0.0001), more often men (66.7% vs. 
47.3%; P = 0.0007), had higher STS PROM (16.3 ± 8.0 vs 10.4 ± 5.6; P < 0.0001), and higher rates of diabetes mellitus (57.5% vs. 39.7%; 
P = 0.0017). Outcomes at 30 days were comparable between groups.
30 Day Outcomes ESRDN=87
Extreme Risk
N=639
All-cause mortality or major stroke, % 5.8 11.1
All-cause mortality, % 5.8 9.1
All stroke, % 2.3 5.1
Major stroke, % 1.2 3.5
Life-threatening/disabling bleeding, % 3.5 15.4
Major vascular complications, % 4.6 8.3
Aortic valve hospitalizations, % 4.8 7.2
KCCQ improvement from baseline 26.4 ± 24.7 20.7 ± 30.6
Conclusion:  Despite more co-morbidities, ER pts with ESRD and severe aortic stenosis have similar early clinical outcomes and 
improvement in quality of life as pts without ESRD. Long term studies will provide additional information about the sustained benefit of 
TAVR in these pts.
